WO2003025003A3 - Hiv-gag codon-optimised dna vaccines - Google Patents

Hiv-gag codon-optimised dna vaccines Download PDF

Info

Publication number
WO2003025003A3
WO2003025003A3 PCT/EP2002/010592 EP0210592W WO03025003A3 WO 2003025003 A3 WO2003025003 A3 WO 2003025003A3 EP 0210592 W EP0210592 W EP 0210592W WO 03025003 A3 WO03025003 A3 WO 03025003A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
fragment
dna vaccines
gag
optimised dna
Prior art date
Application number
PCT/EP2002/010592
Other languages
French (fr)
Other versions
WO2003025003A2 (en
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Wely Catherine Ann Van
Original Assignee
Glaxo Group Ltd
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Wely Catherine Ann Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Priority to US10/490,011 priority Critical patent/US20070015721A1/en
Priority to MXPA04002631A priority patent/MXPA04002631A/en
Priority to HU0402259A priority patent/HUP0402259A3/en
Priority to BR0212619-2A priority patent/BR0212619A/en
Priority to NZ531814A priority patent/NZ531814A/en
Priority to AU2002362368A priority patent/AU2002362368B2/en
Priority to EP02798748A priority patent/EP1427826B1/en
Application filed by Glaxo Group Ltd, Andrew Beaton, Peter Franz Ertl, Gerald Wayne Gough, Andrew Lear, John Philip Tite, Wely Catherine Ann Van filed Critical Glaxo Group Ltd
Priority to DE60239815T priority patent/DE60239815D1/en
Priority to KR1020047004128A priority patent/KR101067231B1/en
Priority to IL16080902A priority patent/IL160809A0/en
Priority to AT02798748T priority patent/ATE506439T1/en
Priority to CA002461056A priority patent/CA2461056A1/en
Priority to JP2003528849A priority patent/JP4601956B2/en
Publication of WO2003025003A2 publication Critical patent/WO2003025003A2/en
Publication of WO2003025003A3 publication Critical patent/WO2003025003A3/en
Priority to ZA2004/02189A priority patent/ZA200402189B/en
Priority to NO20041157A priority patent/NO331826B1/en
Priority to HK04109687.5A priority patent/HK1066830A1/en
Priority to US12/015,756 priority patent/US20090203144A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.
PCT/EP2002/010592 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines WO2003025003A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AT02798748T ATE506439T1 (en) 2001-09-20 2002-09-18 CODONE-OPTIMIZED HIV-RT-NEF-GAG DNA VACCINES
CA002461056A CA2461056A1 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines
JP2003528849A JP4601956B2 (en) 2001-09-20 2002-09-18 HIV-GAG codon optimized DNA vaccine
KR1020047004128A KR101067231B1 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines
HU0402259A HUP0402259A3 (en) 2001-09-20 2002-09-18 Vaccines
BR0212619-2A BR0212619A (en) 2001-09-20 2002-09-18 Nucleotide sequence, vector, protein, pharmaceutical composition, intradermal release device, method for treating a patient suffering from or susceptible to a disease, use of a nucleotide sequence, and process for the production of a nucleotide
NZ531814A NZ531814A (en) 2001-09-20 2002-09-18 Vaccines
AU2002362368A AU2002362368B2 (en) 2001-09-20 2002-09-18 HIV-gag codon-optimised DNA vaccines
EP02798748A EP1427826B1 (en) 2001-09-20 2002-09-18 HIV- RT-nef-Gag codon optimised DNA vaccines
US10/490,011 US20070015721A1 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines
DE60239815T DE60239815D1 (en) 2001-09-20 2002-09-18 Codon-optimized HIV-RT nef-gag DNA vaccines
MXPA04002631A MXPA04002631A (en) 2001-09-20 2002-09-18 Use of immidazoquinolinamines as adjuvants in dna vaccination.
IL16080902A IL160809A0 (en) 2001-09-20 2002-09-18 HIV-gag CODON-OPTIMISED DNA VACCINES
ZA2004/02189A ZA200402189B (en) 2001-09-20 2004-03-18 Hiv-gag codon-optimised dna vaccines
NO20041157A NO331826B1 (en) 2001-09-20 2004-03-19 Nucleotide sequence, vector, protein, pharmaceutical preparation, intradermal delivery device, and method for producing a nucleotide sequence.
HK04109687.5A HK1066830A1 (en) 2001-09-20 2004-12-07 Hiv- rt-nef-gag codon optimised dna vaccines hiv-rt-nef-gag
US12/015,756 US20090203144A1 (en) 2001-09-20 2008-01-17 Hiv-gag codon-optimised dna vaccines

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GBPCT/GB01/04207 2001-09-20
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0129604.5 2001-12-11
GB0206462.4 2002-03-19
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/015,756 Continuation US20090203144A1 (en) 2001-09-20 2008-01-17 Hiv-gag codon-optimised dna vaccines

Publications (2)

Publication Number Publication Date
WO2003025003A2 WO2003025003A2 (en) 2003-03-27
WO2003025003A3 true WO2003025003A3 (en) 2003-12-04

Family

ID=27256076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010592 WO2003025003A2 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines

Country Status (16)

Country Link
US (2) US20070015721A1 (en)
EP (2) EP2322626A1 (en)
JP (1) JP4601956B2 (en)
CN (1) CN100392085C (en)
AR (1) AR036566A1 (en)
AU (1) AU2002362368B2 (en)
BR (1) BR0212619A (en)
CA (1) CA2461056A1 (en)
CO (1) CO5560591A2 (en)
HU (1) HUP0402259A3 (en)
IL (1) IL160809A0 (en)
MX (1) MXPA04002631A (en)
NO (1) NO331826B1 (en)
NZ (1) NZ531814A (en)
PL (1) PL207168B1 (en)
WO (1) WO2003025003A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633866B (en) * 2004-08-05 2015-04-15 葛兰素史密丝克莱恩生物有限公司 Vaccine for preventing and treating HIV infection

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325838D1 (en) * 2002-03-19 2009-03-05 Glaxo Group Ltd IMIDAZOQUINOLINAMINE AS ADJUVANTIES FOR HIV DNA VACCINE
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
DE102004049223A1 (en) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Preparation for vaccination, vaccination and use of a vaccine preparation
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
AU2006245920A1 (en) * 2005-05-12 2006-11-16 Glaxo Group Limited Vaccine composition
EP2099486A2 (en) * 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
SI2137210T1 (en) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Novel method and compositions
BRPI0811228A2 (en) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A LYOPHILIZED COMPOSITION, AND METHODS TO PRODUCE A LIOFILIZED COMPOSITION AND TO PRODUCE AN IMMUNOLOGICAL COMPOSITION.
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
WO2011043830A2 (en) 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
BRPI0914507A2 (en) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz recombinant yellow fever vaccine-based lentivirus vaccine
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PL3333265T3 (en) 2010-05-14 2020-08-10 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from hepatitis b virus and uses thereof
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
RS57397B8 (en) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
DK2964769T3 (en) 2013-03-05 2018-12-10 Univ Oregon Health & Science Cytomegalovirus vectors enabling control of T cell targeting
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
CN113528466A (en) 2014-07-16 2021-10-22 俄勒冈健康与科学大学 Human cytomegalovirus comprising exogenous antigen
MA40783A (en) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS
CA2976245A1 (en) 2015-02-10 2016-08-18 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
RU2722149C1 (en) 2015-09-14 2020-05-27 Пфайзер Инк. New derivatives of imidazo [4,5-c] quinolines and imidazo [4,5-c] [1,5] naphthyridines as lrrk2 inhibitors
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
KR102604486B1 (en) 2016-10-18 2023-11-22 오레곤 헬스 앤드 사이언스 유니버시티 Cytomegalovirus vectors that induce T cells restricted by major histocompatibility complex molecules
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009378A1 (en) * 1994-09-19 1996-03-28 The General Hospital Corporation Overexpression of mammalian and viral proteins
WO1997031115A2 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Synthetic hiv genes
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2001088141A2 (en) * 2000-05-18 2001-11-22 Geneart Gmbh Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2002099101A1 (en) * 2001-06-01 2002-12-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69031951T2 (en) 1989-11-16 1998-08-13 Du Pont Transformation of animal skin cells with the help of particles
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
AU674815B2 (en) 1994-01-21 1997-01-09 Powderject Vaccines, Inc. Gas driven gene delivery instrument
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
OA12156A (en) * 1999-11-16 2006-05-08 Geneart Gmbh Geschellschaft Fu The genome of the HIV-1 inter-subtype (C/B') and use thereof.
BR0016510A (en) * 1999-12-23 2002-08-27 Medical Res Council Improvements in or related to immune responses to HIV

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009378A1 (en) * 1994-09-19 1996-03-28 The General Hospital Corporation Overexpression of mammalian and viral proteins
WO1997031115A2 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Synthetic hiv genes
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
WO2001088141A2 (en) * 2000-05-18 2001-11-22 Geneart Gmbh Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2002099101A1 (en) * 2001-06-01 2002-12-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRAF M ET AL: "CONCERTED ACTION OF MULTIPLE CIS-ACTING SEQUENCES IS REQUIRED FOR REV DEPENDENCE OF LATE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 GENE EXPRESSION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 22, November 2000 (2000-11-01), pages 10822 - 10826, XP000971716, ISSN: 0022-538X *
HUANG YUE ET AL: "Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.", JOURNAL OF VIROLOGY, vol. 75, no. 10, May 2001 (2001-05-01), pages 4947 - 4951, XP002237413, ISSN: 0022-538X *
KOTSOPOULOU E ET AL: "A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 10, May 2000 (2000-05-01), pages 4839 - 4852, XP002140792, ISSN: 0022-538X *
SCHNEIDER R ET AL: "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows rev-independent expression of gag and gag/protease and particle formation", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 7, July 1997 (1997-07-01), pages 4892 - 4903, XP002137891, ISSN: 0022-538X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633866B (en) * 2004-08-05 2015-04-15 葛兰素史密丝克莱恩生物有限公司 Vaccine for preventing and treating HIV infection

Also Published As

Publication number Publication date
IL160809A0 (en) 2004-08-31
AU2002362368B2 (en) 2006-09-21
BR0212619A (en) 2004-08-17
PL207168B1 (en) 2010-11-30
US20070015721A1 (en) 2007-01-18
WO2003025003A2 (en) 2003-03-27
CN100392085C (en) 2008-06-04
MXPA04002631A (en) 2004-07-08
EP1427826B1 (en) 2011-04-20
JP4601956B2 (en) 2010-12-22
CN1606624A (en) 2005-04-13
AR036566A1 (en) 2004-09-15
NZ531814A (en) 2005-10-28
NO20041157L (en) 2004-05-19
US20090203144A1 (en) 2009-08-13
HUP0402259A2 (en) 2005-01-28
EP1427826A2 (en) 2004-06-16
JP2005511019A (en) 2005-04-28
NO331826B1 (en) 2012-04-16
CO5560591A2 (en) 2005-09-30
PL370359A1 (en) 2005-05-16
CA2461056A1 (en) 2003-03-27
EP2322626A1 (en) 2011-05-18
HUP0402259A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
WO2000029561A8 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2005034992A3 (en) Hiv vaccines based on env of multiple clades of hif
PT956360E (en) Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses
IN2009KN02655A (en)
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
GB2351290A (en) Retroviral delivery sytem
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2004041851A3 (en) Vaccine
MY131949A (en) Vaccines
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
WO2003004055A3 (en) Nucleic acid adjuvants
WO2002022663A3 (en) Stress resistant retroviruses
GB0202569D0 (en) Delivery means
HUP0500099A2 (en) Glucuronyl c5-epimerase, dna encoding the same and uses thereof
WO2001007625A3 (en) Ehrlichia canis genes and vaccines
AU2002341238A1 (en) Diabetic model

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 160809

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002798748

Country of ref document: EP

Ref document number: 2003528849

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/02189

Country of ref document: ZA

Ref document number: 531814

Country of ref document: NZ

Ref document number: 200402189

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2461056

Country of ref document: CA

Ref document number: 2002362368

Country of ref document: AU

Ref document number: 00369/KOLNP/2004

Country of ref document: IN

Ref document number: 369/KOLNP/2004

Country of ref document: IN

Ref document number: PA/a/2004/002631

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047004128

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028230876

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002798748

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007015721

Country of ref document: US

Ref document number: 10490011

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500367

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 531814

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 531814

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 10490011

Country of ref document: US